Recent Finacing
Recent Raise
Affylmmune develops CAR-T for solid tumors using a "Tune & Track" platform to adjust CAR affinity, reduce toxicity, extend persistence and enable tracking; lead AIC1000 is in Phase 1.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at AffyImmune Therapeutics.
